SG131594G - Expression of human proapolipoprotein A-1 - Google Patents

Expression of human proapolipoprotein A-1

Info

Publication number
SG131594G
SG131594G SG131594A SG131594A SG131594G SG 131594 G SG131594 G SG 131594G SG 131594 A SG131594 A SG 131594A SG 131594 A SG131594 A SG 131594A SG 131594 G SG131594 G SG 131594G
Authority
SG
Singapore
Prior art keywords
proapolipoprotein
sequence
expression
expression vectors
dna sequences
Prior art date
Application number
SG131594A
Other languages
English (en)
Inventor
Alex Bollen
Jean Gobert
Ernst Wuelfert
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Sa filed Critical Ucb Sa
Priority to SG131594A priority Critical patent/SG131594G/en
Publication of SG131594G publication Critical patent/SG131594G/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG131594A 1987-05-28 1994-09-12 Expression of human proapolipoprotein A-1 SG131594G (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SG131594A SG131594G (en) 1987-05-28 1994-09-12 Expression of human proapolipoprotein A-1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB878712540A GB8712540D0 (en) 1987-05-28 1987-05-28 Expression of human proapolipoprotein a-i
SG131594A SG131594G (en) 1987-05-28 1994-09-12 Expression of human proapolipoprotein A-1

Publications (1)

Publication Number Publication Date
SG131594G true SG131594G (en) 1995-01-13

Family

ID=10618034

Family Applications (1)

Application Number Title Priority Date Filing Date
SG131594A SG131594G (en) 1987-05-28 1994-09-12 Expression of human proapolipoprotein A-1

Country Status (33)

Country Link
US (1) US5059528A (de)
EP (1) EP0293357B1 (de)
JP (1) JP2634193B2 (de)
KR (1) KR970000808B1 (de)
CN (1) CN1031892C (de)
AT (1) ATE89006T1 (de)
AU (1) AU615654B2 (de)
CA (1) CA1323851C (de)
CY (1) CY1809A (de)
CZ (1) CZ283648B6 (de)
DD (1) DD291093A5 (de)
DE (1) DE3880739T2 (de)
DK (1) DK175686B1 (de)
EG (1) EG19101A (de)
ES (1) ES2054878T3 (de)
FI (1) FI100056B (de)
GB (1) GB8712540D0 (de)
HK (1) HK137794A (de)
HU (1) HU204562B (de)
IE (1) IE62422B1 (de)
IL (1) IL86480A (de)
LT (1) LT3600B (de)
LV (1) LV5288A3 (de)
NO (1) NO179253C (de)
NZ (1) NZ224808A (de)
PL (1) PL158064B1 (de)
PT (1) PT87562B (de)
RU (1) RU2009198C1 (de)
SG (1) SG131594G (de)
SK (1) SK363888A3 (de)
SU (1) SU1834904A3 (de)
UA (1) UA19765A (de)
ZA (1) ZA883824B (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
JP2606228B2 (ja) * 1987-09-18 1997-04-30 三菱化学株式会社 ヒトプロアポリポプロテインａ−ｉ様蛋白の産生法
EP0345155B1 (de) * 1988-05-31 1994-08-10 Mitsubishi Kasei Corporation Verfahren zur Herstellung von Proteinen, die ähnlich dem natürlich-menschlichen Apolipoprotein-E sind
US5846799A (en) * 1988-06-14 1998-12-08 La Region Wallone Human myeloperoxidase and its therapeutic application
US5460961A (en) * 1988-06-14 1995-10-24 La Region Wallonne Human myeloperoxidase and its therapeutic application
IT1229996B (it) * 1989-04-20 1991-09-20 Cesare Sirtori Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
ATE158816T1 (de) * 1990-11-26 1997-10-15 Genetics Inst Expression von pace in wirtszellen und verfahren zu dessen verwendung
US5844097A (en) * 1990-11-30 1998-12-01 Monoclonetics International, Inc. Methods for the diagnosis of peripheral nerve damage
ES2083152T3 (es) * 1990-11-30 1996-04-01 Monoclonetics Int Metodos para el diagnostico de dolores cronicos lumbares y cervicales.
GB9508618D0 (en) * 1995-04-28 1995-06-14 Applied Research Systems Therapeutic protein
SE9500778D0 (sv) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US5994061A (en) * 1995-09-29 1999-11-30 Queen's University At Kingston DNA constructs and methods for screening for increased expression of human apo AI gene
SE9603068D0 (sv) * 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603303D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
KR100330355B1 (ko) * 1999-06-04 2002-04-01 장인순 회전유동발생 날개를 가진 덕트형 핵연료 집합체 지지격자
US20040047853A1 (en) * 2000-06-09 2004-03-11 Dahl Soren W Purified proenzyme of dipeptidyl peptidase i (pro-dppi)
CA2431210A1 (en) * 2000-12-12 2002-06-20 Lexicon Genetics Incorporated Novel human kinases and uses thereof
KR100560102B1 (ko) * 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
US7427662B2 (en) * 2005-02-01 2008-09-23 Baord Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Inhibition of angiogenesis and destruction of angiogenic vessels by apolipoprotein A-I and high density lipoprotein
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
EP1917278A2 (de) * 2005-08-26 2008-05-07 Cerenis Therapeutics Holding SA Zusammensetzungen und verfahren für die herstellung von apolipoprotein gene produkten in lactic acid bakterien
US20080293102A1 (en) * 2007-02-28 2008-11-27 Cerenis Therapeutics Holding, S.A. Compositions and methods for producing apolipoprotein
CN102239260B (zh) * 2008-10-03 2017-04-12 库尔纳公司 通过抑制针对载脂蛋白‑a1的天然反义转录物治疗载脂蛋白‑a1相关疾病
CN111808084A (zh) 2008-11-10 2020-10-23 阿布特斯生物制药公司 用于递送治疗剂的新型脂质和组合物
EP3243504A1 (de) 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Verbesserte lipidformulierung
AU2010223967B2 (en) 2009-03-12 2015-07-30 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
SG10201911942UA (en) 2009-05-05 2020-02-27 Muthiah Manoharan Lipid compositions
CN103223177B (zh) 2009-05-06 2016-08-10 库尔纳公司 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
KR101766408B1 (ko) 2009-06-10 2017-08-10 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
AP2015008874A0 (en) 2009-08-14 2015-11-30 Alnylam Pharmaceuticals Inc Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
EP3296398A1 (de) 2009-12-07 2018-03-21 Arbutus Biopharma Corporation Zusammensetzungen für nukleinsäurefreisetzung
EP3494963A1 (de) 2009-12-18 2019-06-12 The University of British Columbia Verfahren und zusammensetzungen zur abgabe von nukleinsäuren
US20130156845A1 (en) 2010-04-29 2013-06-20 Alnylam Pharmaceuticals, Inc. Lipid formulated single stranded rna
US20130137628A1 (en) 2010-05-11 2013-05-30 Esperion Therapeutics, Inc. Dimeric Oxidation-Resistant Apolipoprotein A1 Variants
KR20190039347A (ko) 2010-06-03 2019-04-10 알닐람 파마슈티칼스 인코포레이티드 활성제의 전달을 위한 생분해성 지질
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012064824A1 (en) 2010-11-09 2012-05-18 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
CA2824526C (en) 2011-01-11 2020-07-07 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
HUE042314T2 (hu) 2011-02-07 2019-06-28 Cerenis Therapeutics Holding Sa Lipoprotein komplexek és azok gyártása és alkalmazásai
EP3456317B1 (de) 2011-09-27 2025-09-24 Alnylam Pharmaceuticals, Inc. Substituierte di-aliphatic pegylierte lipide
WO2014011908A1 (en) 2012-07-11 2014-01-16 Esperion Therapeutics, Inc. Apolipoprotein mixtures
DK2992098T3 (da) * 2013-05-01 2019-06-17 Ionis Pharmaceuticals Inc Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression
EP2853259A1 (de) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Rekonstituierte hochdichte Lipoproteinzusammensetzung und Verwendungen davon
CA2947127A1 (en) 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Hdl therapy markers
WO2018077159A1 (zh) * 2016-10-27 2018-05-03 中国科学院微生物研究所 氨基酸衰减子的改造方法及其在生产中的应用
ES2984286T3 (es) 2017-08-10 2024-10-29 Abionyx Pharma Sa Apómeros
EP3668600B1 (de) 2017-08-10 2024-05-15 Abionyx Pharma SA Cargomere
US11081113B2 (en) 2018-08-24 2021-08-03 Bright Marbles, Inc. Idea scoring for creativity tool selection
US11164065B2 (en) 2018-08-24 2021-11-02 Bright Marbles, Inc. Ideation virtual assistant tools
US11461863B2 (en) 2018-08-24 2022-10-04 Bright Marbles, Inc. Idea assessment and landscape mapping
US11189267B2 (en) 2018-08-24 2021-11-30 Bright Marbles, Inc. Intelligence-driven virtual assistant for automated idea documentation
MX2022012969A (es) 2020-04-16 2022-11-09 Abionyx Pharma Sa Metodos para el tratamiento de condiciones agudas usando complejos basados en proteinas de union a lipidos.
IL301769A (en) 2020-10-01 2023-05-01 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
MX2023012223A (es) 2021-04-15 2023-10-26 Abionyx Pharma Sa Uso de complejos a base de proteinas de union a lipidos en soluciones de conservacion de organos.
AU2023250345A1 (en) 2022-04-06 2024-11-14 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
CN119317440A (zh) 2022-04-06 2025-01-14 阿比奥尼克斯制药公司 使用基于脂质结合蛋白的复合物治疗白细胞增多、内皮功能障碍和心脏炎的方法
IL317448A (en) 2022-06-10 2025-02-01 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using complexes based on lipid-binding proteins
JP2025519606A (ja) 2022-06-10 2025-06-26 アビオニクス ファーマ エスエー 脂質結合タンパク質に基づく複合体を使用して急性状態を処置するための方法
IL322074A (en) 2023-01-13 2025-09-01 Abionyx Pharma Sa Treatment using a lipid-binding protein molecule
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
JPS6198998A (ja) 1984-10-18 1986-05-17 Matsushita Electric Ind Co Ltd 電動送風機
BE901119A (fr) 1984-11-23 1985-03-15 Wallone Region Procede de preparation de plasmides vecteurs capables de transformer un hote bacterien escherichia coli et d'y promouvoir et controler l'expression d'un adn heterologue.
AU580145B2 (en) 1985-02-13 1989-01-05 Scios Nova Inc. Human metallothionein-ii promoter in mammalian expression system
GB8507833D0 (en) * 1985-03-26 1985-05-01 Biogen Nv Production of human somatomedin c
EP0239631A4 (de) 1985-10-04 1989-01-12 Biotech Res Partners Ltd Rekombinante apolipoproteine und verfahren.
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
EP0269260A3 (de) * 1986-10-29 1988-06-22 Biotechnology Research Partners, Ltd. ApoAI-C-III-AIV, apoAII, apoB, apoCI und LDL-Rezeptor-Polymorphismus für genetischen Fingerabdruck und Atherosklerosevorhersage

Also Published As

Publication number Publication date
CZ283648B6 (cs) 1998-05-13
LV5288A3 (lv) 1993-10-10
ATE89006T1 (de) 1993-05-15
FI882456L (fi) 1988-11-29
LTIP828A (en) 1995-02-27
PT87562B (pt) 1992-09-30
DE3880739D1 (de) 1993-06-09
SU1834904A3 (ru) 1993-08-15
JP2634193B2 (ja) 1997-07-23
CN88103118A (zh) 1988-12-14
HU204562B (en) 1992-01-28
LT3600B (en) 1995-12-27
AU1672388A (en) 1988-12-01
HK137794A (en) 1994-12-16
JPS6416589A (en) 1989-01-20
HUT47153A (en) 1989-01-30
CY1809A (en) 1995-10-20
KR970000808B1 (en) 1997-01-20
SK279166B6 (sk) 1998-07-08
EP0293357A1 (de) 1988-11-30
PT87562A (pt) 1989-05-31
IL86480A (en) 1992-08-18
SK363888A3 (en) 1998-07-08
PL272698A1 (en) 1989-03-06
PL158064B1 (pl) 1992-07-31
NO179253C (no) 1996-09-04
DD291093A5 (de) 1991-06-20
DK289688A (da) 1988-11-29
CZ363888A3 (cs) 1998-02-18
CN1031892C (zh) 1996-05-29
DE3880739T2 (de) 1993-08-19
FI100056B (fi) 1997-09-15
US5059528A (en) 1991-10-22
IL86480A0 (en) 1988-11-15
ZA883824B (en) 1989-02-22
ES2054878T3 (es) 1994-08-16
CA1323851C (en) 1993-11-02
DK289688D0 (da) 1988-05-27
GB8712540D0 (en) 1987-07-01
UA19765A (uk) 1997-12-25
EG19101A (en) 1994-09-29
AU615654B2 (en) 1991-10-10
NO882341L (no) 1988-11-29
KR880014110A (ko) 1988-12-22
IE62422B1 (en) 1995-02-08
FI882456A0 (fi) 1988-05-25
RU2009198C1 (ru) 1994-03-15
IE881597L (en) 1988-11-28
EP0293357B1 (de) 1993-05-05
DK175686B1 (da) 2005-01-17
NZ224808A (en) 1990-01-29
NO882341D0 (no) 1988-05-27
NO179253B (no) 1996-05-28

Similar Documents

Publication Publication Date Title
KR970000808B1 (en) Human proapolipoprotein a-1 expression
ES2059354T3 (es) Un metodo para producir un polipeptido.
NO910797D0 (no) Dna-fragment som koder for et polypeptid med nitrilhydratase-aktivitet, en transformant inneholdende genet og en fremgangsmaate for fremstilling av amider ved bruk av transformanten.
NO940736L (no) DNA sekvenser som koder for gelonin polypeptid
NO177570C (no) Fremgangsmåte ved fremstilling av peptider med fibronektinbindende egenskaper, mikroorganisme og DNA-sekvens som koder for peptider med fibronektinbindende egenskaper
HUT52551A (en) Process for production of neutrophil-activizating factor
IL110942A0 (en) Grb3-3 gene, its variants and their uses
IL99079A0 (en) Protein structure of the plant toxin gelonin
GB9215232D0 (en) Vaccines
FR2556365B1 (fr) Vecteurs de clonage et d'expression de l'interferon-g, bacteries transformees et procede de preparation de l'interferon-g
DE60027928D1 (de) MENSCHLICHES, GEBäRMUTTERKREBS-SPEZIFISCHES SUPPRESSORPROTEIN, FüR DAS PROTEIN KODIERES POLYNUKLEOTID, MIT DEM POLYNUKLEOTID TRANSFORMIERTE ZELLE UND VERFAHREN ZUR UNTERDRüCKUNG DER PROLIFERATION VON KREBSZELLEN UNTER VERWENDUNG DES EXPRESSIONSVEKTORS
DE69031996D1 (de) Menschlicher rekombinanter plazentaler ribonuklease-inhibitor und verfahren zur herstellung
DE69636737D1 (de) Neues immunoregulatorisches protein lst-1